What is the main business of Solinea Pharmaceuticals?

The main business activity of Solinea Pharmaceuticals focuses on office administrative service activities.

When was the company founded?

The company was registered in the Polish National Court Register (KRS) on September 7, 2015.

Where is the headquarters located?

The headquarters is located at: ul. Szafranowa 6, 21-003 Elizówka.

Who is on the management board?

The management board includes Mariusz Tomasz Trus (President of the Management Board).

What is the share capital?

The share capital of the company is PLN 5,000 (approx. $1,351).

What period do the latest financial data cover?

The latest available financial statement covers the period from January 1, 2024 to December 31, 2024.

What was the revenue?

In 2024, the company generated total revenue of $957,800, representing an increase of 29.6% compared to 2023.

Yes, the company recorded a net profit of $31,328 in 2024, meaning the company increased its profit by 122.9%.

What is the largest operating cost?

The largest operating cost category falls under employee remuneration. This category amounted to $635,979 in 2024, representing 69% of all operating expenses.

Solinea Pharmaceuticalssp. z o.o.

Office administrative service activities

KRS: NIP: REGON:

Overview

Status

Active

Registry date

2015-09-07

Share capital

5,000.00 PLN

Activity description

Solinea Pharmaceuticals is a Polish pharmaceutical company operating in the healthcare sector. It develops and supplies health products, with a range of more than 150 products.

Registered address

ul. Szafranowa 6, 21-003 Elizówka, Poland

Website

solinea.pl

Phone

Social media

Electronic delivery address

AE:PL-60551-62509-UEARH-26

Financials

Revenue history (in k)

Filing timeliness

2 of 6 financial statements were filed late (the longest delay 360 days for 2022).

202513/07/2026
202411/07/2025
202309/07/2024
202209/07/2024
202114/10/2022
202030/09/2021

Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2025.

Results vs industry

Revenue

This companyUSD 1.05mMedianUSD 49.58kAverageUSD 1.46m

Net profit

This companyUSD 24.89kMedianUSD 2.10kAverageUSD 196.41k

Operating costs

This companyUSD 1.02mMedianUSD 44.02kAverageUSD 1.15m

Assets

This companyUSD 346.44kMedianUSD 40.01kAverageUSD 9.73m

News

2025-08-26

Fertistim ovu – patented Caronositol FertilityⓇ formula recommended for women with PCOS and fertility support

2024-12-02

Muconasin – over-the-counter nasal spray with N-acetylcysteine

2024-06-29

Fertistim for women – inositol sachets for PCOS, insulin resistance, and prolonged attempts to conceive

2023-07-17

Ectodose inhalation solution with ectoine over-the-counter, new packaging

Industry

Office administrative service activities (82.11.Z)Primary

Offer

Prescription medicines
Over-the-counter medicines
Dietary supplements
Medical devices
Cosmetics

Website technology

Website

WordPress

Analytics and marketing

Google Analytics
Google Tag Manager

Authorized Representatives

Katarzyna Lidia Grosner – Attorney-in-fact (sole)

Mariusz Tomasz Trus – President of the Management Board

Manner of representation

Each member of the management board is authorized to make declarations on behalf of the company independently.

Ownership

Owner	Shares	Share value	Stake
Solpharma Plus sp. z o.o.	50	$1,350.62	100%

Beneficial owners

Person	Rights

Bank accounts

Registered as a VAT taxpayer on 2015-10-13.

ING Bank Śląski
92 1050 1953 1000 0090 3071 0058

Debt

No entries in the National Debtors Register (KRZ).

Public aid

6 public aid cases recorded, with a total value of $90,829.

Grant date	Purpose	Gross amount	Granting body
May 12, 2021	De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier)	$325$325	DRUGI URZĄD SKARBOWY W LUBLINIE
Jun 29, 2020	Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts	$5,515$5,515	Prezes Zakładu Ubezpieczeń Społecznych
May 30, 2020	Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts	$5,764$5,764	Prezes Zakładu Ubezpieczeń Społecznych

Competitors

	Name	Revenue	Website
	Contact PharmS.K.A.	$825,293.63	contactpharm.pl
	Inno4medsp. z o.o.	$140,269.98	inno4med.pl

Change history

Date	Event
2023-10-13	Address change (65, 21-003, Elizówka → Ul. Szafranowa 6, 21-003, Elizówka)
2021-02-23	Address change (65/Hala L, 21-003, Elizówka → 65, 21-003, Elizówka)
2020-09-11	Address change (65/Hala I, 21-003, Elizówka → 65/Hala L, 21-003, Elizówka)
2015-09-07	Entered in the register

FAQ

Last updated: 2026-10-07